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Abstract 
Immunoassay formats applicable for clinical or point-of-care diagnostics fall into two broad 
classes. One which uses labeled secondary antibodies for signal transduction and the other which 
does not require the use of any labels. Comparison of the limits of detection (LoD) reported by 
these two sensing approaches over a wide range of detection techniques and target molecules in 
serum revealed that labeled techniques achieve 2-3 orders of magnitude better LoDs. Further, a 
vast majority of commercial tests and recent examples of technology translations are based on 
labeled assay formats. In light of this data, it is argued that extension of traditional labeled 
approaches and enhancing their functionality may have better clinical impact than the 
development of newer label-free techniques.  
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Is a “mobile phone revolution” possible in personalized diagnostics? 
Ubiquitous access to Information and Communication Technology (ICT), particularly, 
wireless communication technologies, has radically transformed our lives with mobile-enabled 
technologies applied in areas ranging from education and entertainment to healthcare [1]. The 
deep penetration of mobile technologies, even in economically underdeveloped nations, is 
expected to provide better living conditions through mobile-enabled services in such countries. 
Analogous to the mobile revolution, we would like to see a radical transformation in human 
health monitoring enabled by ubiquitous access to affordable personal healthcare devices for 
continuous monitoring of human health parameters. The health parameters may include 
macroscopic state variables such as heart rate, ECG (Echocardiogram) and blood pressure as 
well as microscopic state variables such as the concentration of biomarker (text in bold is a 
glossary item) proteins in serum. One could use the example of ICT to imagine what the key 
enablers for such a transformation in personal health monitoring would be. Firstly, there should 
be sensing platforms or techniques where economies of scale can be applied to enable deep 
global penetration through cost reduction. In the case of ICT, Silicon based integrated electronics 
technology played this role [1]. In the case of personalized health monitoring it remains to be 
seen if such a universal platform technology would emerge. Secondly, not only the hardware 
cost, which is the capital expense, but also the recurring usage cost must be low. In the case of 
ICT this was possible due to the same economies of scale operating in the Silicon semiconductor 
manufacturing which led to low unit cost of data usage. In the case of healthcare devices, low 
usage cost translates to low unit cost of testing in terms of consumables required such as sensors 
and reagents. Finally, these devices must be easy to use with minimal user intervention required. 
This is necessary for the widespread adoption of such technology and to encourage its frequent 
use.  
 
Methods for diagnostic testing: labeled and label-free Immunoassays  
Currently health monitoring consists of a few simple tests which are possible at the 
clinician’s office such as blood-pressure or ECG and a large number of tests requiring 
centralized testing labs causing delays of up to a few days between testing and results [2,3]. As a 
result, data from continuous monitoring of a given individual over his/her lifespan for parameters 
even as simple as blood-pressure are not easily available. Such datasets collected over a large 
number of individuals over time may reveal as yet undiscovered strategies for disease 
management or prevention. For several diseases including certain cancers, early detection 
exponentially improves the survival rate [4]. Even though one may not need day to day or even 
weekly testing frequency in these cases, there is certainly arguable merit in the development of 
sensing technologies which could perhaps be used at home and are capable of deep global 
penetration making early diagnosis accessible across economic strata.   
Diagnostic tests are typically done using blood samples and are generally based on the 
immunoassay format where an antibody or a receptor is bound on a solid surface [5,6, Box 1]. 
These receptors bind the target biomarker from blood/serum or the sample under consideration. 
Ambitious goals such as early cancer detection requires the detection of biomarkers present in 
blood at extremely low concentrations with a high level of specificity using a system with few 
process steps for ease of use [7, 8]. Two broad classes of biosensors emerge depending on how 
the binding of target molecules is detected by the sensing instrument. The first class includes 
gold standards such as ELISA (Enzyme Linked Immunosorbent Assay) where a secondary 
antibody with a suitable label molecule conjugated to it, binds to the target-receptor complex 
immobilized on the surface [Box 1]. A better alternative, to enable ease of use, would be to 
detect the binding of the target molecules to the receptors directly without any secondary 
antibody labels. This approach is called label-free detection. By eliminating the need for labels 
and associated sample processing steps, label-free systems can potentially operate with minimal 
or no user intervention. By combining this simplicity of testing with the ability to detect small 
concentrations of biomarkers in complex samples such as serum, easy to use label-free sensors 
hold the promise of radically transforming personalized health diagnostics in a way comparable 
to the transformation of data communication with the advent of mobile phones.  
 
 
 
 
 
 
 
 
  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Box 1: Immunoassay format
The solid phase immunoassay format developed during the 60’s and 70’s is a method to detect 
the presence of proteins or other molecules 
a solid surface such as glass, nitrocellulose or 
(blue Y shaped objects in the figure) immobilized on the solid surface capture the target 
molecules (red spheres) from the sample containing other molecules (blue spheres) which may 
potentially interfere by binding to the antibodies. This is called non
binding of the molecules (target or non
appropriately chosen surface blocking steps s
entirely due to the interaction of the sample with the immobilized antibodies. Recently 
researchers have also developed other ways to capture target mo
(specific DNA sequences), instead of antibodies. In general, the basic idea of immunoassay is 
that receptor molecules immobilized on a solid surface capture specific targets from a sample. In 
any given assay there will be some
accounted for while interpreting the measurement. 
depending on the detection of target receptor binding. 
conjugated with a label (blue Y shape with a green star attached to it) is used to bind to the 
target molecules captured by the immobilized antibodies making a sandwich structure. The 
signal is read out using properties of the label. For example, the label
which emits light with a certain color
colored product as in ELISA tests 
The labeling process and the incubation with secondary 
steps as well as increases the usage cost of such tests. As a result, several groups ha
techniques not requiring the use of labe
optical refractive index, electrical conductance or mass change associated with the capture of 
target molecules. Such assays are called label
antibodies. 
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Comparison of limit of detection of labeled and label-free sensors 
Label-free sensors have witnessed decades of development with a veritable zoo of 
techniques available today exploiting physical effects as exotic as superconducting quantum 
interference [11]. However, in spite of this intense activity, most real-world tests including FDA 
approved tests are still based on labeled formats such as ELISA and immuno-fluorescence assays 
[12] and almost all recent examples from literature describing translation of diagnostic 
technology to real-world applications are also based on the labeled format [2,5-8,13-16]. It is 
therefore very important now to critically compare the performance of labeled and label-free 
technologies to understand if there are systematic reasons for the lack of prevalence for label-free 
technologies. To assess the current state of performance of label-free techniques, I compared the 
nearly 120 limit of detection (LoD) values reported for label-free and labeled methods for serum 
based biomarker detection. There were significant differences in the surface functionalization 
and assay protocols followed by different research groups reporting these LoDs. Consequently 
such a comparison may suffer from biases arising from the sensitivity of the LoD to the specific 
experimental protocols. To better compare these two approaches, I identified reports where 
labeled and label-free assays were performed simultaneously, eliminating any bias arising from 
differences in experimental protocols. Finally, I also examined recent examples describing 
translation of sensing techniques into real-world applications. It was found that labeled 
techniques significantly outperformed label-free techniques in all these contexts. In light of this 
observation, I argue that extension of traditional labeled assays into lab-on-chip formats and 
enhancing their performance using innovative signal read-out methods may have a better clinical 
impact than the frenzied development of newer label-free techniques we have witnessed in recent 
times.  
The LoDs reported by various groups for a range of protein biomarkers, including those 
related to cancer were examined [17-76]. The complete data set along with the search strings 
used in the bibliographic database Web of Science [77] for literature survey is provided in 
Supplmentary Data Table [78]. Only articles reporting LoDs in serum were considered. For each 
category of data, namely, labeled and label-free, the cumulative distribution function (CDF) 
[Box 2] of the reported LoD values was constructed. A metric referred here as LoD50 was 
defined based on the CDF. The LoD50 is the LoD value for which the CDF function reaches the 
mid-point. The LoD50 value therefore represents a kind of weighted average of the LoDs 
reported for each category. There were 54 data points for labeled detection and 53 data points for 
label-free detection making the comparison reasonable. Further, this comparison was done across 
proteins ranging from 10 kDa to 600 kDa with assays varying in the antibodies/receptors used, 
surface functionalization protocols and signal detection methods spanning mechanical, electrical, 
electrochemical and optical domains involving techniques as wide as Surface Plasmon 
Resonance, e.g. [41], micro-cantilevers, e.g. [51], fluorescence-immunoassays, e.g. [32], ELISA 
e.g. [54], optical interferometry, e.g. [25] and Silicon nanowires, e.g. [26]. Therefore, the data 
collected was a comprehensive representation of serum based labeled and label-free detection 
approaches. In order to extract the LoD50 value in an objective manner, the data points were 
fitted with a smooth curve. As seen in Fig. 2 (a), the LoD50 value of labeled detection was about 
0.1 pM (pico-Molar) while that of label-free detection was around 10 pM indicating a 3 orders of 
magnitude gap in LoDs in favor of labeled detection methods. An examination of the high 
performing label-free detection techniques, depicted as “label-free outliers” in Fig. 2 a) revealed 
that all of them used significant amplification of the signal by using secondary antibodies tagged 
with micron sized beads, nanoparticles or enzymes. Use of such tagged secondary antibodies is 
contrary to the label-free detection paradigm and it is debatable whether these techniques should 
indeed be classified as label-free. Such reports were classified in a new category called “Label-
free secondary amplified” and a reanalysis of the data was done. Out of the 53 data points in the 
label-free category, 30 of them, i.e. more than 50%, used secondary amplification. The CDF of 
the different sensing approaches classified into labeled, label-free and label-free secondary 
amplified is shown in Fig. 2 (b). Understandably, amplification of the label-free signal using 
secondary antibodies results in an order of magnitude improvement achieving an LoD50 value 
around 3 pM compared to the LoD50 of about 30 pM for direct label-free detection. However this 
performance is still nearly two orders of magnitude worse than that achieved by labeled detection 
which has a LoD50 around 0.1 pM.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To check if there was any correlation between reported LoDs with the molecular mass of 
the target biomarker, the data was re-plotted in the manner shown in Fig. 2 (c). The horizontal 
axis is the reported LoD in pM (pico-molar) while the vertical axis is the molecular weight of the 
target biomarker. Red, green and blue stripes represent labeled, label-free secondary amplified 
and direct label-free LoDs respectively. We do not see any correlation associated with the 
different targets considered. In other words the conclusions drawn from Figs. 2 (a) and (b) are 
valid across the entire range of target biomarkers considered. The conclusion emerging from this 
analysis is that labeled detection techniques are 2-3 orders of magnitude more sensitive than 
label-free approaches and it is only after significant signal amplification using tagged secondary 
antibodies that label-free approaches can attain similar performance.  
Box 2: Cumulative Distribution Function  
Cumulative Distribution Function (CDF) is a function used in statistics to characterize the 
distribution of observed values of a variable [79]. CDF curves are generally normalized to a 
maximum of one so that the range of CDF is always from 0 to 1. The value of a normalized 
CDF curve for a variable V at x, denoted by CDFV(x), represents the probability that a random 
measurement of V would turn up a value less than x. For e.g. if the CDF for some variable V at x 
= 100 is 0.05, it means that it is very unlikely for measurements of V to yield values less than 
100. We should expect the measurement of V to almost always yield values greater than 100. In 
the context of this article, CDF(x) represents the probability that a given research article in the 
respective detection category (labeled or label-free) would report a LoD less than x. For 
example, the value of CDF curve for label-free detection at LoD of 1 pM is about 0.25 (Figure 2 
(a)) while it is about 0.9 for labeled detection. This means that if we picked a random research 
article dealing with label-free detection there is only a 25% chance that it would report a LoD of 
less than 1 pM while there is a 90% chance that the reported LoD would be less than 1 pM if the 
article was dealing with labeled detection. This is the basis for the observation that labeled 
techniques appear to outperform label-free methods. To construct the approximate CDF curve 
from a set of observed values, we rank the observations in ascending order and use 
1
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−
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N
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xCDF   where R(x) is the rank (position) of x in the sorted list of observations and 
N is the total number of observations in the set. We then plot CDF(x) against x for each 
observed value in the set to obtain the CDF curves shown in Fig. 2 (a) and (b).   
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of the labeled technique. The log10 ratio of the label-free to labeled LoD is plotted on the right 
vertical axis. The mean log10 LoD ratio is around 3 which supports the conclusion from Fig. 2 
(a) and (b) that labeled techniques achieve 2-3 orders magnitude better LoDs compared to label-
free techniques.  
 
Data from simultaneous labeled and label-free assays 
 As mentioned earlier, LoD is sensitive to surface functionalization methods and 
associated experimental protocols. As there are likely to be major variations in these parameters 
for the data shown in Fig. 2 (a), the best way to compare the two different detection approaches 
would be to measure the same assay using a labeled and a label-free method simultaneously. 
Although few in number, some research groups have indeed done such experiments enabling 
direct comparison of labeled and label-free detection techniques without any confounding factors 
[24,33,61,72,73]. Fig. 2 (d) plots the label-free LoD on the horizontal axis against the LoD 
reported for corresponding labeled assay on the left vertical axis. On the right vertical axis the 
base-10 logarithm of the ratio of label-free LoD to the labeled LoD is plotted. For every single 
data point in Fig. 2 (d), it is seen that labeled LoD was significantly better than the corresponding 
label-free LoD. Moreover, the mean log10 ratio of label-free LoD to the labeled LoD of about 3 
supports the conclusions drawn from the previous analysis, namely that labeled approaches 
achieve 2-3 orders of magnitude better LoDs than label-free techniques.   
 
Examination of outlier technologies 
It is interesting to examine the best performers in each category to identify techniques 
that show the highest promise. In the case of labeled detection, Plasmonic ELISA [35] and 
Digitial ELISA [54] report the best LoDs. In the case of label-free detection, inverse sensitivity 
assay employing enzyme mediated nanoparticle synthesis [34], massive signal amplification with 
1 micron diameter magnetic beads [29], with enzyme conjugated magnetic beads [52] and so on 
report the best LoDs. However as pointed out earlier, this approach is only superficially different 
from using fluorophore or enzyme labels as done in labeled immunoassays and it is debatable if 
they should even be considered as label-free techniques. Direct label-free detection using Si 
nanowires has reported extremely low LoDs using desalted serum [36]. However, desalting may 
pose sample pre-treatment challenges. More importantly, such a dramatic performance advantage 
of nanowires over other label-free techniques such as SPR, micro-nano-mechanical resonators or 
even electrochemical methods must really be supported on firm theoretical grounds which is 
currently lacking. To summarize, the analysis of LoDs reported in serum strongly suggests that 
secondary antibody labels are required to achieve performance compared to traditional labeled 
techniques such as ELISA or fluorescence immunoassays. However, amplification using tagged 
secondary antibodies runs contrary to the label-free detection paradigm of direct detection with 
minimal sample processing and perhaps such approaches shouldn’t even be considered as label-
free.  
 
Why might label-free assays perform worse than labeled assays? 
Secondary antibody amplified label-free LoD50 is still at least an order of magnitude worse 
than the LoD50 of labeled approach even though both approaches use labels. Ignoring 
multiplicative factors, LoD can be written as SLoD
noiseσ
= where noiseσ is the noise floor of 
measurement and S is the sensitivity of the measurement technique [80]. It is believed that the 
noise floor in the current generation of biosensors mostly arises from non-specific binding (NSB) 
processes, for e.g., binding of interfering molecules to the receptors [81]. In this case, the noise 
floor will be the standard deviation of signal produced by a negative control sample, which in the 
case of serum based tests will be serum devoid of the target biomarker. In the case of labeled 
techniques, noiseσ mainly arises from NSB of the secondary antibody to the target biomarker or 
unblocked sensor surface. However, in the case of label-free approaches, irrespective of whether 
they are amplified or not, noiseσ can arise due to the NSB of the secondary antibody, NSB of the 
target biomarker, erosion of receptors [67] or similar phenomena related to the functionalization 
layers. In other words the noise floor of label-free detection is likely to be larger than that of 
labeled approaches. The improvement in LoD50 for secondary antibody tagged amplified label-
free sensors arises from increased sensitivity (larger S) due to signal amplification. This is a 
plausible model to explain the observations in Fig. 2.  
 
Conclusions and implications for clinical assay development  
Perhaps related to the observations made above, examination of commercial tests for FDA 
approved serum biomarkers [12] or the list of recent examples demonstrating the translation of 
biosensing techniques from lab to the real world [2,5-8,13-16], we see that almost all of them are 
based on labeled assay formats with color based or fluorescence readouts. It is impossible to find 
even a single example in this domain which uses a sophisticated label-free technique such as 
nanowires or nano-mechanical resonators. On the other hand many of these technology 
translations employ clever variations of the labeled detection strategies. In this regard, recent 
extensions of conventional labeled detection techniques such as Digital-ELISA [55], Plasmonic-
ELISA [35], inverse sensitivity assay [34] and so on, show great promise. In light of these 
observations, I argue that extension of traditional labeled assays into lab-on-chip formats and 
enhancing their performance using innovative signal read-out methods may have a better clinical 
impact than the continued development of newer label-free techniques leading to a highly 
fragmented techno-commerical landscape unlike the dominant Silicon semiconductor platform 
technology which formed the basis for the digital revolution. Digital-ELISA and Plasmonic-
ELISA are notable recent examples in this direction. However, this is not to suggest that label-
free techniques serve no purpose. There are several applications involving detection of molecules 
in simple samples such as buffers, or those involving large molecules or markers that appear in 
large concentration, where label-free techniques may indeed leverage their simplicity and cost 
advantages. However, when the requirement is to measure ultra-low (sub pM) concentration of 
markers from a complex sample such as serum, it appears that labeled detection strategies 
currently have a significant performance advantage over label-free techniques. It is hoped that 
the data presented here will stimulate discussions leading to a critical and realistic assessment of 
the capabilities of label-free techniques and help identify applications where their unique 
strengths can be exploited. 
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Glossary Items 
 
Biomarkers: Biomarkers are molecules whose concentration in serum could indicate a 
diseased condition or predict the imminent development of disease. For e.g. elevated serum 
concentration of a protein called Prostate Specific Antigen (PSA) could indicate the presence 
of prostate cancer.  
ELISA: Enzyme Linked Immunosorbent Assay (ELISA) is a commonly used immunoassay 
format where an enzyme labelled secondary antibody is used to bind targets captured by 
primary antibodies immobilized on a solid surface. Signal detection is based on the color 
change produced by the action of the enzyme on molecules referred to as substrate.  
Fluorophore: A fluorophore is a molecule which can absorb light around a peak absorption 
wavelength and emit light at slightly longer wavelengths. They can be used for labelling 
secondary antibodies in labelled immunoassays.  
Immunoassay: Immunoassay is the term used to describe the method to test for the presence 
of a molecule of interest, referred to as the target, using another molecule having a specific 
affinity for the target, such as an antibody against the target.  
LoD: Limit of Detection (LoD) is the smallest concentration of targeted molecule that can be 
detected by a sensing technique. It is directly proportional to the ratio of noise floor of 
measurement and the sensitivity.  
Sensitivity: Sensitivity of a sensor is the slope of the signal response to the stimulus. In the 
case of biosensors, it is the signal response per unit change in the concentration of the target 
molecule.  
Serum: Serum is the fraction of blood without the cells and clotting factor. It contains 
several potential biomarkers.  
 
 
          
 This is the supplementary data table for the article Limitations of Label-Free Sensors 
in Serum Based Molecular Diagnostics; Manoj M. Varma. The table below shows the 
limit of detection (LoD) collected for several label-free (LF) and labeled immunoassay 
methods. Label-free detection is further classified into LF direct and LF sec amp. "LF 
sec amp" refers to the use of tagged secondary antibodies for signal amplification. 
The reference numbers are provided as they occur in the main text. The search 
strings used for collecting this data are given in the next sheet. 
 
  
  
  
  
          
Mole
cule 
Molec
ular 
weigh
t 
(Mw) 
in 
Literat
ure 
Mw 
Assu
med 
(kDa) 
Detec
tion 
Categ
ory 
Technique Sample Type LoD 
(From 
Ref) 
LoD 
(ng/m
L) 
LoD 
(pM) 
Refere
nce 
PSA ~ 30 
kDa 
30 Labele
d 
FL 
(Fluorescen
ce) 
goat serum 1 fg/mL 0.000
001 
3.33E
-05 
17 
PSA ~ 30 
kDa 
30 Labele
d 
SPR 
(Surface 
Plasmon 
Resonance) 
enhanced 
FL 
female human 
plasma 
2 pg/mL 0.002 6.67E
-02 
18 
IL-1 
(a/b) 
17 kDa 17 LF 
direct 
Fiber Optic 
SPR 
4% bovine 
serum 
1 ng/mL 1 5.88E
+01 
19 
IL-6 23.7 
kDa 
23.7 LF 
direct 
Fiber Optic 
SPR 
CCM (Cell 
Culture 
Media) with 
4% FBS (Fetal 
Bovine Serum)  
1 ng/mL 1 4.22E
+01 
19 
TNF-a ~ 17 
kDa 
17 LF 
direct 
Fiber Optic 
SPR 
CCM with 10% 
FBS 
1 ng/mL 1 5.88E
+01 
19 
IL-6 23.7 
kDa 
23.7 Labele
d 
Luminex pooled human 
plasma 
0.75 
pg/mL 
0.000
75 
3.16E
-02 
20 
IL-6 23.7 
kDa 
23.7 Labele
d 
ELISA pooled human 
plasma 
70 
fg/mL 
0.000
07 
2.95E
-03 
20 
IL-8 ~ 10 
kDa 
10 Labele
d 
Luminex 
(Bead FL) 
pooled human 
plasma 
1.3 
pg/mL 
0.001
3 
1.30E
-01 
20 
IL-8 ~ 10 
kDa 
10 Labele
d 
ELISA pooled human 
plasma 
0.26 
pg/mL 
0.000
26 
2.60E
-02 
20 
PSA ~ 30 
kDa 
30 LF 
direct 
Si NW desalted 
donkey serum 
1 pg/mL 0.001 3.33E
-02 
21 
PSA ~ 30 
kDa 
30 LF sec 
amp 
Si cantilever fetal bovine 
serum 
50 
fg/mL 
0.000
05 
1.67E
-03 
22 
IFN-g 17 - 19 
KDa 
18 Labele
d 
MSD (Meso 
Scale 
Discovery) 
spiked human 
plasma 
0.7 
pg/mL 
0.000
7 
3.89E
-02 
23 
IL-2  15.3 
kDa 
15.3 Labele
d 
Luminex spiked human 
plasma 
8.7 
pg/mL 
0.008
7 
5.69E
-01 
23 
IL-2  15.3 
kDa 
15.3 Labele
d 
MSD spiked human 
plasma 
2.5 
pg/mL 
0.002
5 
1.63E
-01 
23 
IL-4 15 kDa 15 Labele
d 
Luminex spiked human 
plasma 
8.6 
pg/mL 
0.008
6 
5.73E
-01 
23 
IL-4 15 kDa 15 Labele
d 
MSD spiked human 
plasma 
0.7 
pg/mL 
0.000
7 
4.67E
-02 
23 
IL-8 ~ 10 
kDa 
10 Labele
d 
Luminex spiked human 
plasma 
7.7 
pg/mL 
0.007
7 
7.70E
-01 
23 
IL-8 ~ 10 
kDa 
10 Labele
d 
MSD spiked human 
plasma 
0.7 
pg/mL 
0.000
7 
7.00E
-02 
23 
TNF-a ~ 17 
kDa 
17 Labele
d 
Luminex spiked human 
plasma 
6 pg/mL 0.006 3.53E
-01 
23 
TNF-a ~ 17 
kDa 
17 Labele
d 
MSD spiked human 
plasma 
3 pg/mL 0.003 1.76E
-01 
23 
PSA ~ 30 
kDa 
30 Labele
d 
SPR enh FL human serum 10 
pg/mL 
0.01 3.33E
-01 
24 
PSA ~ 30 
kDa 
30 LF 
direct 
SPR human serum 10 
ng/mL 
10 3.33E
+02 
24 
PSA ~ 30 
kDa 
30 LF sec 
amp 
Reflectance human serum 4 ng/mL 4 1.33E
+02 
25 
PSA ~ 30 
kDa 
30 LF 
direct 
Si nanowire native human 
serum 
10 
ng/mL 
10 3.33E
+02 
26 
IL-1 
(a/b) 
17 kDa 17 Labele
d 
Luminex, 
MSD etc 
human serum ~ 
1pg/mL 
0.001 5.88E
-02 
27 
IL-2  15.3 
kDa 
15.3 Labele
d 
Luminex spiked human 
serum 
2.1 
pg/mL 
0.002
1 
1.37E
-01 
27 
IL-6 23.7 
kDa 
23.7 Labele
d 
Luminex human serum 0.6 
pg/mL 
0.000
6 
2.53E
-02 
27 
PSA ~ 30 
kDa 
30 LF sec 
amp 
QCM 
(Quartz 
Crystal 
Microbalan
ce) 
75% human 
serum 
300 
pg/mL 
0.3 1.00E
+01 
28 
PSA ~ 30 
kDa 
30 LF sec 
amp 
SPR calf serum 10 
fg/mL 
0.000
01 
3.33E
-04 
29 
PSA ~ 30 
kDa 
30 LF sec 
amp 
SPR calf serum 10 
pg/mL 
0.01 3.33E
-01 
29 
IL-1 
(a/b) 
17 kDa 17 Labele
d 
FL human serum 12 
pg/mL 
0.012 7.06E
-01 
30 
IL-6 23.7 
kDa 
23.7 Labele
d 
FL spiked human 
serum 
4.3 
pg/mL 
0.004
3 
1.81E
-01 
30 
TNF-a ~ 17 
kDa 
17 Labele
d 
FL spiked human 
serum 
5 pg/mL 0.005 2.94E
-01 
30 
IL-6 23.7 
kDa 
23.7 Labele
d 
Luminex human serum 1.6 
pg/mL 
0.001
6 
6.75E
-02 
31 
IL-6 23.7 
kDa 
23.7 Labele
d 
MSD human serum 1 pg/mL 0.001 4.22E
-02 
31 
IL-8 ~ 10 
kDa 
10 Labele
d 
Luminex human serum 4 pg/mL 0.004 4.00E
-01 
31 
IL-8 ~ 10 
kDa 
10 Labele
d 
MSD human serum 0.2 
pg/mL 
0.000
2 
2.00E
-02 
31 
IFN-g 17 - 19 
KDa 
18 Labele
d 
Luminex human Serum 1 pg/mL 0.001 5.56E
-02 
32 
IL-2  15.3 
kDa 
15.3 Labele
d 
Luminex spiked human 
serum 
1.1 
pg/mL 
0.001
1 
7.19E
-02 
32 
IL-4 15 kDa 15 Labele
d 
Luminex spiked human 
serum 
0.6 
pg/mL 
0.000
6 
4.00E
-02 
32 
IL-5 15.2 
kDa 
15.2 Labele
d 
Luminex spiked human 
serum 
2.7 
pg/mL 
0.002
7 
1.78E
-01 
32 
IL-6 23.7 
kDa 
23.7 Labele
d 
Luminex spiked human 
serum 
4.6 
pg/mL 
0.004
6 
1.94E
-01 
32 
IL-8 ~ 10 
kDa 
10 Labele
d 
Luminex spiked human 
serum 
1 pg/mL 0.001 1.00E
-01 
32 
TNF-a ~ 17 
kDa 
17 Labele
d 
Luminex spiked human 
serum 
600 
fg/mL 
0.000
6 
3.53E
-02 
32 
TNF-a ~ 17 
kDa 
17 LF 
direct 
SPR buffer 1 ng/mL 1 5.88E
+01 
33 
TNF-a ~ 17 
kDa 
17 Labele
d 
SP coupled 
FL 
buffer 10 
pg/mL 
0.01 5.88E
-01 
33 
TNF-a ~ 17 
kDa 
17 Labele
d 
ELISA  buffer 100 
pg/mL 
0.1 5.88E
+00 
33 
PSA ~ 30 
kDa 
30 LF sec 
amp 
LSPR human serum 1 
attog/m
L 
1E-09 3.33E
-08 
34 
PSA ~ 30 
kDa 
30 LF sec 
amp 
LSPR human serum 1 
attog/m
1E-09 3.33E
-08 
35 
L 
PSA ~ 30 
kDa 
30 LF 
direct 
Si nanowire human serum 5 fg/mL 
(dubiou
s) 
0.000
005 
1.67E
-04 
36 
PSA ~ 30 
kDa 
30 Labele
d 
FL human serum 0.8 
pg/mL 
0.000
8 
2.67E
-02 
37 
PSA ~ 30 
kDa 
30 LF sec 
amp 
SPR 20% human 
serum 
5 ng/mL 5 1.67E
+02 
38 
ALCA
M 
65 kDa 65 LF 
direct 
SPR 10% human 
serum 
20 
ng/mL 
20 3.08E
+02 
39 
ALCA
M 
65 kDa 65 Labele
d 
ELISA human serum 0.1 
ng/mL 
0.1 1.54E
+00 
39 
ALCA
M 
65 kDa 65 LF 
direct 
SPR human serum 64 
ng/mL 
64 9.85E
+02 
40 
ALCA
M 
65 kDa 65 LF 
direct 
imaging 
SPR 
10% human 
plasma 
45 
ng/mL 
45 6.92E
+02 
41 
ALCA
M 
65 kDa 65 LF 
direct 
Suspended 
microchann
el resonator 
(SMR)  
undiluted fetal 
bovine serum 
10 
ng/mL 
10 1.54E
+02 
42 
CA12
5 
0.2 - 1 
MDa 
600 LF 
direct 
QCM human 
serum/plasma 
5 U/mL 5 8.33E
+00 
43 
CA12
5 
0.2 - 1 
MDa 
600 LF 
direct 
Electrical 
impedance 
human plasma 1 U/mL 1 1.67E
+00 
44 
CA12
5 
0.2 - 1 
MDa 
600 LF 
direct 
Electroche
mical 
human serum 0.1 
U/mL 
0.1 1.67E
-01 
45 
CA12
5 
0.2 - 1 
MDa 
600 LF 
direct 
Optical 
cavity  
human serum 1.8 
U/mL 
1.8 3.00E
+00 
46 
IL-2  15.3 
kDa 
15.3 Labele
d 
Electroche
miluminesc
ence 
human serum 1 pg/mL 0.001 6.54E
-02 
47 
IL-4 15 kDa 15 LF sec 
amp 
Electroche
milum 
human serum 2 pg/mL 0.002 1.33E
-01 
47 
TNF-a ~ 17 
kDa 
17 Labele
d 
Bead FL human serum 3 pg/mL 0.003 1.76E
-01 
48 
TNF-a ~ 17 
kDa 
17 Labele
d 
ELISA  human serum 5 pg/mL 0.005 2.94E
-01 
48 
IL-2  15.3 
kDa 
15.3 LF sec 
amp 
MRR 
(micro-ring 
resonator) 
CCM with 10% 
FBS 
1.9 
ng/mL 
1.9 1.24E
+02 
49 
IL-4 15 kDa 15 LF sec 
amp 
MRR CCM with 10% 
FBS 
1 ng/mL 1 6.67E
+01 
49 
IL-5 15.2 
kDa 
15.2 LF sec 
amp 
MRR CCM with 10% 
FBS 
3.4 
ng/mL 
3.4 2.24E
+02 
49 
TNF-a ~ 17 
kDa 
17 LF sec 
amp 
MRR CCM with 10% 
FBS 
4.6 
ng/mL 
4.6 2.71E
+02 
49 
IL-8 ~ 10 
kDa 
10 Labele
d 
FL human serum 26 
pg/mL 
0.026 2.60E
+00 
50 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
Si cantilever human serum 100 
fg/mL  
0.000
1 
4.22E
-03 
51 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
Electroche
mical 
calf serum 10 
fg/mL 
0.000
01 
4.22E
-04 
52 
IL-8 ~ 10 
kDa 
10 LF sec 
amp 
Electroche
mical 
calf serum 10 
fg/mL 
0.000
01 
1.00E
-03 
52 
IL-2  15.3 
kDa 
15.3 LF sec 
amp 
MRR CCM with 10% 
FBS 
~ 10 
pg/mL 
0.01 6.54E
-01 
53 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
MRR CCM with 10% 
FBS 
~ 10 
pg/mL 
0.01 4.22E
-01 
53 
IL-8 ~ 10 
kDa 
10 LF sec 
amp 
MRR CCM with 10% 
FBS 
~ 10 
pg/mL 
(check) 
0.01 1.00E
+00 
53 
IL-1 
(a/b) 
17 kDa 17 Labele
d 
ELISA bovine serum 30 
fg/mL 
0.000
03 
1.76E
-03 
54 
IL-6 23.7 
kDa 
23.7 Labele
d 
Digital 
ELISA 
spiked bovine 
serum 
24 
fg/mL 
0.000
024 
1.01E
-03 
54 
TNF-a ~ 17 
kDa 
17 Labele
d 
Digital 
ELISA 
human serum 70 
fg/mL 
0.000
07 
4.12E
-03 
54 
IFN-g 17 - 19 
KDa 
18 Labele
d 
FL human serum 6 pg/mL 0.006 3.33E
-01 
55 
IFN-g 17 - 19 
KDa 
18 Labele
d 
Plas Enh 
NIR FL 
10% fetal 
bovine serum 
250 
fg/mL 
0.000
25 
1.39E
-02 
55 
IL-1 
(a/b) 
17 kDa 17 Labele
d 
Plas Enh 
NIR FL 
10% fetal 
bovne serum 
70 
fg/mL 
0.000
07 
4.12E
-03 
55 
IL-4 15 kDa 15 Labele
d 
Plas Enh 
NIR FL 
10% fetal 
bovne serum 
1.3 
pg/mL 
0.001
3 
8.67E
-02 
55 
IL-6 23.7 
kDa 
23.7 Labele
d 
Plas Enh 
NIR FL 
10% fetal 
bovne serum 
60 
fg/mL 
0.000
06 
2.53E
-03 
55 
TNF-a ~ 17 
kDa 
17 Labele
d 
Plas Enh 
NIR FL 
10% fetal 
bovne serum 
470 
fg/mL 
0.000
47 
2.76E
-02 
55 
IFN-g 17 - 19 
KDa 
18 LF 
direct 
SPR 100x diluted 
bovine serum 
250 
ng/mL 
250 1.39E
+04 
56 
IFN-g 17 - 19 
KDa 
18 LF 
direct 
Electroche
mical 
RPMI/10% 
fetal bovine 
serum 
5 ng/mL 5 2.78E
+02 
57 
IFN-g 17 - 19 
KDa 
18 LF 
direct 
SPR 2% depleted 
human plasma  
10 
ng/mL 
10 5.56E
+02 
58 
IFN-g 17 - 19 
KDa 
18 LF sec 
amp 
Electroche
mical 
fetal bovine 
serum 
200 
ng/mL 
200 1.11E
+04 
59 
IFN-g 17 - 19 
KDa 
18 LF 
direct 
Chemilumin
escence 
5% human 
serum 
20 
ng/mL 
20 1.11E
+03 
60 
Rabbi
t IgG 
150 
kDa 
150 Labele
d 
BioCD 
(Interferom
etry) 
bovine serum 30 
pg/mL 
0.03 2.00E
-01 
61 
Rabbi
t IgG 
150 
kDa 
150 LF 
direct 
BioCD bovine serum 250 
pg/mL 
0.25 1.67E
+00 
61 
Rabbi
t IgG 
150 
kDa 
150 LF sec 
amp 
BioCD bovine serum 70 
pg/mL 
0.07 4.67E
-01 
61 
IL-2  15.3 
kDa 
15.3 LF 
Direct 
BSI 
(Backscatte
ring 
Interferome
try) 
media 
containing 1% 
serum 
150 
pg/mL 
0.15 9.80E
+00 
62 
IL-2  15.3 
kDa 
15.3 LF sec 
amp 
MRR CCM with 10% 
FBS 
1 ng/mL 1 6.54E
+01 
63 
IL-8 ~ 10 
kDa 
10 LF sec 
amp 
MRR CCM with 10% 
FBS 
1 ng/mL 1 1.00E
+02 
63 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
Electroche
mical 
serum 410 
fg/mL 
0.000
41 
1.73E
-02 
64 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
SPR CCM with 10% 
FBS 
2 ng/mL 2 8.44E
+01 
65 
IL-6 23.7 
kDa 
23.7 LF 
direct 
SPR CCM with 10% 
FBS 
> 12 
ng/mL 
12 5.06E
+02 
65 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
GMR (Giant 
Magneto-
resistance) 
serum 9 pg/mL 0.009 3.80E
-01 
66 
IL-6 23.7 
kDa 
23.7 LF 
direct 
Reflectance buffer 19 
ng/mL 
19 8.02E
+02 
67 
IL-6 23.7 
kDa 
23.7 LF sec 
amp 
Reflectance buffer 2 ng/mL 2 8.44E
+01 
67 
IL-6 23.7 
kDa 
23.7 Labele
d 
Nano Enh 
FL 
buffer and 
serum 
12.9 
attog/m
L 
1.3E-
08 
5.49E
-07 
68 
IL-8 ~ 10 
kDa 
10 LF sec 
amp 
SPR human saliva 2.2 
ng/mL 
2.2 2.20E
+02 
69 
PSA ~ 30 
kDa 
30 LF sec 
amp 
Si cantilever human serum 30 
fg/mL 
0.000
03 
1.00E
-03 
70 
PSA ~ 30 
kDa 
30 LF sec 
amp 
Electroche
mical 
100% human 
serum 
1 ng/mL 1 3.33E
+01 
71 
PSA ~ 30 
kDa 
30 LF sec 
amp 
Electroche
mical 
10% human 
serum 
0.1 
ng/mL 
0.1 3.33E
+00 
71 
ssDN
A 
(25bp
) 
8.2 
kDa 
8.2 LF 
direct 
imaging 
SPR 
Buffer 10 nM   1.00E
+04 
72 
ssDN
A 
(25bp
) 
8.2 
kDa 
8.2 LF 
direct 
QCM Buffer 250 nM   2.50E
+05 
72 
ssDN
A 
(25bp
) 
8.2 
kDa 
8.2 Labele
d 
FL Buffer 1 - 10 
pM 
  5.00E
+00 
72 
Estrad
iol 
272 
Da 
0.272 Labele
d 
ELISA Buffer; 4 diff 
Abs in 3 diff 
sensing 
methods 
7.3 nM   7.30E
+03 
73 
Estrad
iol 
272 
Da 
0.272 LF 
direct 
SPR Buffer 20 nM   2.00E
+04 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
FL Buffer  40 pM   4.00E
+01 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
ELISA Buffer  0.3 nM   3.00E
+02 
73 
Estrad
iol 
272 
Da 
0.272 LF 
direct 
SPR Buffer 20 nM   2.00E
+04 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
FL Buffer  2 pico M   2.00E
+00 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
ELISA Buffer  0.6 nM   6.00E
+02 
73 
Estrad
iol 
272 
Da 
0.272 LF 
direct 
SPR Buffer 49 nM   4.90E
+04 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
FL Buffer  20 pM   2.00E
+01 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
ELISA Buffer  0.3 nM   3.00E
+02 
73 
Estrad
iol 
272 
Da 
0.272 LF 
direct 
SPR Buffer 4.3 nM   4.30E
+03 
73 
Estrad
iol 
272 
Da 
0.272 Labele
d 
FL Buffer  2 pico M   2.00E
+00 
73 
ALCA
M 
65 kDa 65 Labele
d 
ELISA diluted serum 0.03 
ng/mL 
0.03 4.62E
-01 
74 
CA12
5 
0.2 - 1 
MDa 
600 Labele
d 
Luminex human serum 2.7 
pg/mL 
0.02 3.33E
-02 
75 
PSA ~ 30 
kDa 
30 Labele
d 
ELISA human serum 10 
pg/mL 
0.01 3.33E
-01 
76 
 
Search Strings Used 
Technique Technology Variant Search String 
Labeled Fluorescence/ELISA (ts = sens* OR ts = assay) AND (ti = fluor* OR ti = ELISA) AND 
(ts = analyte) 
Label-free (LF) 
generic 
All (ts = sens* OR ts = assay) AND (ts = "label free" OR ts = 
label-free) AND (ts = analyte) 
Limit of 
detection 
All (ts = "limit of detection") AND (ts = analyte) 
LF Optical SPR (ts = sens* OR ts = assay) AND (ts = SPR OR ts = plasmon*) 
AND (ts = analyte) 
Optical cavities, 
Micro-ring resonators 
(ts = sens* OR ts = assay) AND (ts = silicon OR ts = resona*) 
AND (ts = analyte) 
Interferometry (ts = sens* OR ts = assay) AND (ts = interfer*) AND (ts = 
analyte) 
General Optical (ts = sens* OR ts = assay) AND (ts = optic*) AND (ts = 
analyte) 
Reflectance (ts = sens* OR ts = assay) AND (ts = reflect*) AND (ts = 
analyte) 
LF Electrical Nanowire (ts = sens* OR ts = assay) AND (ts = silicon OR ts = nanowire 
OR ts = nano-wire OR ts = CNT OR ts = nano-tube) AND (ts = 
analyte) 
Impedance (ts = sens* OR ts = assay) AND (ts = imped*) AND (ts = 
analyte) 
LF Mass/mech cantilever (ts = sens* OR ts = assay) AND (ts = cantilever OR ts = MEMS 
OR ts = silicon OR ts = micro-mech* OR ts = micromech* OR 
ts = resona*) AND (ts = analyte) 
QCM (ts = sens* OR ts = assay) AND (ts = QCM OR ts = "quartz 
crystal") AND (ts = analyte) 
LF Electrochem Electrochemical (ts = sens* OR ts = assay) AND (ts = electroche*) AND (ts = 
analyte) 
LF magnetic   (ts = sens* OR ts = assay) AND (ts = *magnet*) AND (ts = 
analyte) 
   
  The term "analyte" in the search strings above was 
substituted with the appropriate biomarker, e.g. PSA, IL6 
and so on for each category listed above 
 
 
